Long term adjuvant therapy for primary breast cancer
- PMID: 8601097
- PMCID: PMC2350071
- DOI: 10.1136/bmj.312.7028.389
Long term adjuvant therapy for primary breast cancer
Erratum in
- BMJ 1996 Apr 20;312(7037):992
Comment in
-
Adjuvant treatment with tamoxifen. Local research ethics committees should review their approval of prevention trial.BMJ. 1996 Apr 20;312(7037):1036. doi: 10.1136/bmj.312.7037.1036a. BMJ. 1996. PMID: 8616356 Free PMC article. No abstract available.
-
Adjuvant treatment with tamoxifen. Side effects may have been overstated.BMJ. 1996 Apr 20;312(7037):1036. doi: 10.1136/bmj.312.7037.1036. BMJ. 1996. PMID: 8616357 Free PMC article. No abstract available.
-
Adjuvant treatment with tamoxifen. Recruitment into studies assessing optimum duration of treatment must continue.BMJ. 1996 Apr 20;312(7037):1036-7. doi: 10.1136/bmj.312.7037.1036b. BMJ. 1996. PMID: 8616358 Free PMC article. No abstract available.
-
Adjuvant treatment with tamoxifen. Clinicians must share knowledge with their patients more readily.BMJ. 1996 Apr 20;312(7037):1037. doi: 10.1136/bmj.312.7037.1037a. BMJ. 1996. PMID: 8616359 Free PMC article. No abstract available.
-
Adjuvant treatment with tamoxifen. Multicentre trial should be welcomed.BMJ. 1996 Apr 20;312(7037):1037. doi: 10.1136/bmj.312.7037.1037. BMJ. 1996. PMID: 8616360 Free PMC article. No abstract available.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical